AVI BioPharma, Inc. (AVII) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Research and development: 34.35M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 34.35M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q1 EPS of ($0.13), $0.06 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $11.05 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- Stabilis Solutions, Inc. (SLNG) Tops Q3 EPS by 3c
- National Fuel Gas (NFG) Tops Q4 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
